Certified center

Uro-on­co­lo­gy cent­re for pro­sta­te and kid­ney

Overview & Contact Team Diseases Services Publications

Pu­bli­ca­ti­ons

  • Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J, Gelmann EP, Pollard HB, Srivastava M. Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression. PLoS One. 2018 Oct 15; 13(10).
  • Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, Barrett MT, Rentsch CA, Bubendorf L, Ruiz C. Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. J Pathol. 2018 May; 245(1): 74-84.
  • Offermann A., Vlasic I., Syring I., Vogel W., Ruiz C., Zellweger T., Rentsch C., Hagedorn S., Behrends J., Nowak M., Merseburger A., Bubendorf L., Kirfel J., Duensing S., ShaikhibrahimZ.,Per-ner S.: MED15 overexpression in prostate cancer arises during androgen deprivation therapy via-PI3K/mTOR signalling. Oncotarget. 10 Dec 2016
  • Vedana M, Fuenfschilling M, Tzankov A, Zellweger T.: Primary synovial cell sarcoma of the kidney: case report and review of the literature. 2015 Mar 3;8(1):128-32.
  • Wetterauer C, Vlajnic T, Schüler J, Gsponer JR, Thalmann GN, Cecchini M, Schneider J, Zellweger T, Pueschel H, Bachmann A, Ruiz C, Dirnhofer S, Bubendorf L, Rentsch CA: Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate. 2015 May;75(6):585-92.
  • Vlajnic T, Oeggerli M, Rentsch C, Püschel H, Zellweger T, Thalmann GN, Ruiz C, Bubendorf L.: Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens. Virchows Arch. 2014 Dec;465(6):637-42.
  • Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, Rentsch CA.: Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up. Virchows Arch. 2014 Dec;465(6):629-36.
  • Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocr Relat Cancer. 2014 Aug;21(4):663-75.
  • Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C.: ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31.
  • Shaikhibrahim Z., Offermann A., Braun M., Menon R., Syring I., Nowak M., Halbach R., Vogel W., Ruiz C., Zellweger T., Rentsch C.A., Svensson M., Andren O., Bubendorf L., Biskup S., Duensing S., Kirfel J., Perner S.: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocr Relat Cancer. Aug 2014: 21(4): 663-75.
  • Vlajnic T., Oeggerli M., Rentsch C., Püschel H., Zellweger T., Thalmann G.N., Ruiz C., Bubendorf L.: Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens. Virchows Arch. Dec 2014: 465(6): 637-42.
  • Wetterauer C., Weibel M., Gsponer J.R., Vlajnic T., Zellweger T., Bütikofer S., Müller G., Püschel H., Bachmann A., Gasser T.C., Bubendorf L., Rentsch C.A.: Incidental prostate cancer prevalence at radical cystoprostatectomy - importance of the histopathological workup. Virchows Arch. Dec 2014: 465(6): 629-36.
  • MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
    Shaikhibrahim Z, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S. Int J Cancer. 2014 Jul 1;135(1):19-26.
  • [Renal masses and indication to nephrectomy: preoperative assessment and clinical presentation of five cases]. Vedana M, Geisler S, Zellweger T, Gasser T.
    Rev Med Suisse. 2013 Nov 20;9(407):2184-8.
  • Characterisation and clinical relevance of ALDHbright populations in prostate cancer.
    Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.
    Clin Cancer Res. 2013 Oct 1;19(19):5361-71.
  • Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.
    Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C.
    Endocr Relat Cancer. 2013 May 21;20(3):403-13.
  • ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.
    Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.
    Virchows Arch. 2012 Aug;461(2):157-62.
  • High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.
    Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.
    Prostate. 2012 Nov;72(15):1678-87.
  • Zellweger T., Christ-Crain M.: Is the aging male syndrome still relevant? Swiss Medical Forum 11(51-52):979-980 (2011)
  • Ruiz C., Lenkiewicz E., Evers L., Holley T., Robeson A., Kiefer J., Demeure M.J., Hollingsworth M.A., Shen M., Prunkard D., Rabinovitch P.S., Zellweger T., Mousses S., Trent J.M., Carpten J.D., Bubendorf L., Von Hoff D., Barrett M.T.: Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A. 108(29): 12054-9 (2011)
  • Ruiz C., Holz D.R., Oeggerli M., Schneider S., Gonzales I.M., Kiefer J.M., Zellweger T., Bachmann A., Koivisto P.A., Helin H.J., Mousses S, Barrett M.T., Azorsa D.O., Bubendorf L.: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer Journal of Pathology 223(4): 543-52 (2011)
  • Hailemariam S., Vosbeck J., Cathomas G., Zlobec I., Mattarelli G., Eichenberger T., Zellweger T., Bachmann A., Gasser T.C., Bubendorf L.: Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia? Human Patholology 42(5): 702-9 (2011)
  • Zellweger T.: What to do in case of haematuria Swiss Medical Forum 10 (51-52): 921-23 (2010)
  • Ruiz C., Holz D.R., Oeggerli M., Schneider S., Gonzales I.M., Kiefer J.M., Zellweger T., Bachmann A., Koivisto P.A., Helin H.J., Mousses S., Barrett M.T., Azorsa D.O., Bubendorf L.: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer, Journal of Pathology (2010) Nov. 25.
  • Savic S., Zlobec I., Thalmann G.N., Engeler D., Schmauss M., Lehmann K., Mattarelli G., Eichenberger T., Dalquen P., Spieler P., Schoenegg R., Gasser T.C., Sulser T., Forster T., Zellweger T., Casella R., Bubendorf L.: The prognostic value of cytology and fluorescence in situ hybridisation in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy International Journal of Cancer 124(12): 2899-904 (2009)
  • Zellweger T., Günther S., Zlobec I., Savic S., Sauter G., Moch H., Mattarelli G., Eichenberger T., Curschellas E., Rüfenacht H., Bachmann A., Gasser T.C., Mihatsch M.J., Bubendorf L.: Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. International Journal of Cancer 124(9): 2116-23 (2009)
  • Zellweger T.: Early-stage prostate cancer: wait and see or treat? Swiss Medical Forum 9 (51-52):958-959 (2009)
  • Tan S.H., Dagvadorj A., Shen F., Gu L., Liao Z., Abdulghani J., Zhang Y., Gelmann E.P., Zellweger T., Culig Z., Visakorpi T., Bubendorf L., Kirken R.A., Karras J., Nevalainen M.T.: Transcription factor Stat5 synergises with androgen receptor in prostate cancer cells Cancer Research 68(1): 236-48 (2008)
  • Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., Lisanti M.P., Zellweger T., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., Nevalainen M.T.: Stat3 promotes metastatic progression of prostate cancer, American Journal of Pathology 172(6): 1717-28 (2008)
  • Zellweger T.: Therapy of renal cell carcinoma: No revolution, but a lot of news Swiss Medical Forum 8 (51-52): 1023-1024 (2008)
  • Dagvadorj A., Collins S., Jomain J.B., Abdulghani J., Karras J., Zellweger T., Li H., Nurmi M., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., Goffin V., Nevalainen M.T.: Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signalling pathway Endocrinology 148(7): 3089-101 (2007)
  • Zellweger T., Gasser T.: Urinary incontinence - which therapy and when? Swiss Medical Forum 1: 35-37 (2007)
  • Zellweger T., Benz G., Cathomas G., Mihatsch M., Sulser T., Gasser T., Bubendorf L.: Multi-target fluorescence in situ hybridisation in bladder washings for prediction of recurrent bladder cancer. International Journal of Cancer. 119(7): 1660-1665 (2006)
  • Seiffert H.H., Mazzola B., Zellweger T., Ruszat R., Muller A., Burkhalter F., Steiger J., Sulser T., Bachmann A.: Ureteral obstruction after dextranomer/hyaluronic acid copolymer injection for treatment of secondary vesicoureteral reflux after renal transplantation. Urology 68(1): 203.e17-19 (2006)
  • Zellweger T., Ninck C., Bloch M., Mirlacher M., Koivisto P.A., Mihatsch M.J., Gasser T.C., Bubendorf L.: Expression Patterns of Potential Therapeutic Targets in Prostate Cancer. International Journal of Cancer 113 (4): 619-628 (2005)
  • Zellweger T., Gasser T.: Localised prostate carcinoma: Operate, irradiate or wait? Practice - Swiss Review of Medicine 94(34):1307 -1308 (2005)
  • Li H., Zhang Y., Glass A., Zellweger T., Gehan E., Bubendorf L., Gelmann E., Nevalainen M.T.: Activation of signal transducer and activator of transcription-5 (Stat5) in prostate cancer predicts early recurrence. Clinical Cancer Research 11(16): 5863-5868 (2005)
  • Zellweger T, Gasser T: Benign prostatic hyperplasia: Has the knife had its day? Swiss Medical Forum 5: 1308-09 (2005)
  • Zellweger T., Benz G., Herzog M., Grilli B., Mihatsch M., Gasser T., Bubendorf L.: FISH for an improved estimation of the risk of recurrence after transurethral resection of urothelial carcinomas. German Society for Pathology 88, 194-198 (2004)
  • Zellweger T., Ninck C., Mirlacher M., Glass A.G., Gasser T.C., Mihatsch M.J.,Gelmann E.P., Bubendorf L.: Tissue microarray analysis reveals prognostic importance of syndecan-1 expression in prostate cancer. The Prostate 55: 20-29 (2003)
  • Kiyama S., Morrison K., Zellweger T., Akbari M, Cox M., Miyake H., Yu D.,Gleave M.E.: Antisense IGF-BP-2 oligonucleotides induceapoptosis and delay progression to androgen-independence after castration in human prostate cancer tumour models. Cancer Research 63 (13): 3575-3584 (2003)
  • Zellweger T., Chi K., Kiyama S., Miyake H., Adomat H., Skov K., Gleave M.E.: Over-expression of the cell survival protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. British Journal of Urology 92 (4): 463-469 (2003)
  • Zellweger T., Gasser T.: PSA - curse or blessing? Swiss Medical Forum 51/52: 1284-1286 (2003)
  • July L., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., Gleave M.E.: Clusterin expression is enhanced following androgen withdrawal therapy in prostate cancer patients. The Prostate 15; 50 (3): 179-188 (2002)
  • Zellweger T., Chi K., Miyake H., Adomat H., Kiyama S., Skov K., Gleave M.E.: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research 8 (10): 3276-3284 (2002)
  • Zellweger T., Chi K., Miyake H., Kiyama S., July L.V., Akbari M., Gleave M.E.: Targeting cell survival genes using antisense oligonucleotides to improve chemo- and hormonal therapies in prostate cancer. European Urology Suppl. 1: 7-14 (2002)
  • Gleave M., Zellweger T., Chi K., Miyake H., Kiyama S., July L., Leung S.: Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Investigative New Drugs 20 (2): 145-158 (2002)
  • Leung S., Miyake H., Zellweger T., Gleave M.E.: Synergistic chemosensitisation and inhibition of progression to androgen-independence by antisense bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. International Journal of Cancer 15; 91 (6): 846-850 (2001)
  • Zellweger T., Miyake H., Cooper S., Conklin B., Monia B.P., Gleave M.E.: Pharmaco kinetics of antisense oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy) ethyl chemistry. Journal of Pharmacology and Experimental Therapeutics 298 (3): 934-940 (2001)
  • Gleave M.E., Miyake H., Zellweger T., Chi K., July LV., Nelson C., Rennie P.: Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. Urology 58 (2) Suppl 1 (2001)
  • Zellweger T., Miyake H., July L.V., Akbari M., Kiyama S., Gleave M.E.: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. Neoplasia 3 (4): 360-367 (2001)
  • Miyake H., Hara S., Zellweger T., Kamidono S., Gleave M.E., Hara I.: Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal cell carcinoma cells. Molecular Urology 5 (3): 105-111 (2001)
  • Zellweger T., Ackermann D.: Diagnosis and recurrence prophylaxis of nephrolithiasis. Medical Journal for Switzerland 3, 35-37 (1999)
  • Neuhaus M., Wagner U., Schmid U., Ackermann D., Zellweger T., Maurer R., Alund G.,Knönagel H., Rist M., Moch H., Mihatsch M.J., Gasser Th.C., Sauter G.: Polysomy 1 and 17 but not Y chromosome losses have prognostic significance in superficial urinary bladder cancer. Human Pathology 30 (1): 81-86 (1999)
  • Wagner U., Süess K., Schmid U., Ackermann D., Zellweger T., Maurer R., Alund G., Knönagel H., Rist M., Jordan P., Moch H., Mihatsch M.J., Gasser Th. C., Sauter G.: Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. Journal of Pathology 188 (1): 44-50 (1999)
  • Zhao J., Richter J., Wagner U., Roth B., Schraml P., Zellweger T., Ackermann D., Schmid U., Moch H., Mihatsch M.J., Gasser T.C., Sauter G.: Chromosomal imbalances in noninvasive bladder neoplasms (pTa). Cancer Research 15, 59 (18): 4658-4661 (1999)
  • Zellweger T., Grob R., Buhl D., Müller J., Ackermann D.: Analysis of urinary tract infections in Eastern Switzerland 1993 -1995 Aktuelle Urologie 2, 67-70 (1998)
      • R. Schaffert, P. Rüesch, R. Gügler, S. Fischer, H.P. Schmid, P. Spörri, M. Zurkirchen, R. Ruszat: Information needs of patients with prostate cancer: Pronounced differences between individuals after diagnosis of localised prostate carcinoma. Urologist A 50(9):1089-94 (2011)
      • R. Ruszat, M. Seitz, S.F. Wyler, G. Müller, M. Rieken, G. Bonkat, T.C. Gasser, O. Reich, A. Bachmann. Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporisation of the prostate for treating benign prostatic hyperplasia. BJU Int 104(6):820-5 (2009)
      • U. Walker, A. Tyndall, R. Ruszat. Erectile dysfunction in systemic sclerosis. Ann Rheum Dis 68(7): 1083-5 (2009)
      • A. Bachmann, S. Wyler, T. Wolff, L. Gürke, J. Steiger, C. Kettelhack, T. Gasser, R. Ruszat. Complications of retroperitoneoscopic living donor nephrectomy: single centre experience after 164 cases. World J Urol 26(6): 549-54 (2008)
      • S. Wyler, A. Bachmann, B. Weltzien, T. Gasser, R. Ruszat. Retroperitoneoscopic renal surgery: Indications, technique, and results after 360 procedures. Urologist A 47(8):955-9 (2008)
      • R. Ruszat, M. Seitz, S. Wyler, C. Abe, M. Rieken, O. Reich, T. Gasser, A. Bachmann. Greenlight laser vaporisation of the prostate: Single centre experience and long-term results after 500 procedures. European Urology 54(4):893-901 (2008)
      • R. Ruszat, S. Wyler, M. Seitz, K. Lehmann, C. Abe, G. Bonkat, O. Reich, T. Gasser, A. Bachmann. Comparison of greenlight laser vaporisation of the prostate and transurethral electroresection of the prostate: Update of a prospective non-randomised bi-centric study. BJU int 102(10): 1432-8 (2008)
      • R. Ruszat, S. Wyler, L. Gürke, F. Gambazzi, N. Ebinger, J. Steiger, T. Sulser, T. Gasser, A. Bachmann. Endoscopic management of bisected hemidiaphragm during retroperitoneoscopic donor nephrectomy. Urology 72(5): 1185 (2008)
      • A. Bachmann, R. Ruszat. The KTP- (greenlight-) laser-principles and experiences. Minim Invasive Ther Allied Technol 16(1): 5-10 (2007)
      • A. Bachmann, R. Ruszat. Greenlight laser vaporisation or conventional electroresection of the prostate for the treatment of symptomatic benign prostatic hyperplasia--David against Goliath? Schweiz Rundsch Med Prax 96(3):61-7 (2007)
      • R. Ruszat, S.F. Wyler, T. Wolff, T. Forster, C. Lenggenhager, M. Dickenmann, T. Eugster, L. Gurke, J. Steiger, T.C. Gasser, T. Sulser, A. Bachmann. Reluctance over right-sided retroperitoneoscopic living donor nephrectomy: justified or not? Transplant Proc 39(5):1381-5 (2007)
      • R. Ruszat, S. Wyler, T. Forster, O. Reich, C.G. Stief, T.C. Gasser, T. Sulser, A. Bachmann. Safety and Effectiveness of Photoselective Vaporisation of the Prostate (PVP) in Patients on Ongoing Oral Anticoagulation. Eur Urol 51(4):1031-41 (2007)
      • R. Ruszat, S. Wyler, H.H. Seifert, O. Reich, T. Forster, C.G. Stief, T. Sulser, A. Bachmann. Photoselective vaporisation of the prostate: Experience with prostate adenomas >80 cm(3). Urologist A 45(7):858-864 (2006)
      • R. Ruszat, S. Wyler, H.H. Seifert, O. Reich, T. Forster, T. Sulser, A. Bachmann. Photoselective vaporisation of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol 50(5):1040-9 (2006)
      • R. Ruszat, T. Sulser, M. Dickenmann, T. Wolff, L. Gurke, T. Eugster, I. Langer, P. Vogelbach, J. Steiger, T.C. Gasser, C.G. Stief, A. Bachmann. Retroperitoneoscopic donor nephrectomy: donor outcome and complication rate in comparison with three different techniques. World J Urol 24(1):113-7 (2006)
      • R. Ruszat, R. Casella, A. Bachmann, T.C. Gasser, T. Sulser. Primitive neuroectodermal tumour of the kidney with hyaline cells. Urol Int 75 (2):184-6 (2005)
      • Rüesch P., Schaffert R., Fischer S., Feldman-Stewart D., Ruszat R., Spörri P., Zurkirchen M., Schmid H.P.: Information needs of early-stage prostate cancer patients: within- and between-group agreement of patients and health professionals. Support Care Cancer 22(4):999-1007 (2014)
      • M. Seitz, T. Bayer, R. Ruszat, D. Tilki, A. Bachmann, C. Gratzke, B. Schlenker, C. Stief, R. Sroka, O. Reich. Preliminary evaluation of a novel side-fire diode laser emitting light at 940 nm, for the potential treatment of benign prostatic hyperplasia: ex-vivo and in-vivo investigations. BJU Int 103(6): 770-5 (2009)
      • A. Businger, A. Zettl, S. Sonnet, R. Ruszat, M. von Flüe: Primitive neuroectodermal tumour of the kidney in an adult: a case report. Cases J 5; 2: 6791 (2009)
      • M. Seitz, R. Ruszat, T. Bayer, D. Tilki, A. Bachmann, C. Stief, R. Sroka, O. Reich. Ex vivo and in vivo investigations of the novel 1,470 nm diode laser for potential treatment of benign prostatic enlargement. Lasers Med Sci 24(3): 419-24 (2009)
      • T.H. Forster, G. Bonkat, S. Wyler, R. Ruszat, N. Ebinger, T.C. Gasser, A. Bachmann. Diagnosis and therapy of acute ureteral colic. Wien Klin Wochenschr 120(11-12):325-34 (2008)
      • C. Feder-Mengus, S. Wyler, T. Hudolin, R. Ruszat, L. Bubendorf, A. CHiarugi, M. Pitelli, W.P. Weber, A. Bachmann, T.C. Gasser, T. Sulser, M. Heberer, G.C. Spagnoli, M. Provenzano. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer 44(15): 2266-75 (2008)
      • N. Ebinger, R. Ruszat, T. Forster, S. Wyler, S. Schaub, T. Gasser, A. Bachmann. Superficial papillary bladder tumour with myoglobinuria...Schweiz Med Forum (17):323-325 (2008)
      • M.J. Kim, A. Bachmann, M.J. Mihatsch, R. Ruszat, T. Sulser, M. Mayr. Acute renal failure after continuous flow irrigation in patients treated with potassium-titanyl-phosphate laser vaporisation of the prostate. Am J Kidney Dis 51 (4): e19-24 (2008)
      • H.H. Seifert, B. Mazzola, R. Ruszat, A. Muller, J. Steiger, A. Bachmann, T. Sulser. Transurethral injection therapy with dextranomer/hyaluronic acid copolymer (deflux((r))) for treatment of secondary vesicoureteral reflux after renal transplantation. J Endourol 21(11):1357-60 (2007)
      • T.H. Forster, S. Wyler, R. Ruszat, T.C. Gasser, A. Bachmann. "... The better to see you with"--phothodynamic diagnosis in superficial bladder cancer. Schweiz Rundsch Med Prax 17;96(42):1631-7 (2007)
      • G. Bonkat, R. Ruszat, T. Forster, S. Wyler, V.S. Dogra, A. Bachmann. Benign space-occupying cysts in the testis : An overview. Urology A 46(12):1697-1703 (2007)
      • S. Wyler, A. Bachmann, R. Ruszat, T. Forster, T. Hudolin, T.C. Gasser, T. Sulser. Retroperitoneoscopic nephrectomy for autosomal dominant polycystic kidney disease: initial experience. Urol int 79 (2): 137-41 (2007)
      • M. Seitz, A. Ackermann, C. Gratzke, B. Schlenker, R. Ruszat, A. Bachmann, C. Stief, O. Reich, R. Sroka. Diode laser: Ex vivo studies on vaporisation and coagulation characteristics. Urologist A 46(9):1242-7 (2007)
      • S. Wyler, R. Ruszat, B. Weltzien, T.H. Forster, M. Provenzano, T. Sulser, T.C. Gasser, A. Bachmann. Intermediate-term results of retroperitoneoscopic cryotherapy for small renal tumours using multiple ultrathin cryoprobes. Eur Urol 51(4): 971-9 (2007)
      • S. Wyler, R. Ruszat, U. Straumann, T. Forster, M. Provenzano, T. Sulser, T.C. Gasser, A. Bachmann. Short, intermediate and long-term quality of life after laparoscopic radical prostatectomy- does training of LRP have a negative impact on patients' quality of life? Eur Urol 51(4): 1004-14 (2007)
      • S. Wyler, T. Sulser, HH Seifert, R. Ruszat, T.H. Forster, T.C. Gasser, A. Bachmann. Laparoscopic extended pelvic lymph node dissection for high risk prostate cancer. Urology 68(4): 883-887 (2006)
      • H.H. Seifert, B. Mazzola, T. Zellweger, R. Ruszat, A. Muller, F. Burkhalter, J. Stieger, T. Sulser, A. Bachmann. Ureteral obstruction after dextranomer/hyaluronic acid copolymer injection for treatment of secondary vesicoureteral reflux after renal transplantation. Urology 68(1):203.e17-9 (2006)
      • A. Bachmann, T. Wolff, O. Giannini, M. Dickenmann, R. Ruszat, L. Gurke, M. Kaufmann, T.C. Gasser, J. Steiger, C.G. Stief, T. Sulser. How painful is donor nephrectomy? Retrospective analysis of early pain and pain management in open versus laparoscopic versus retroperitoneoscopic nephrectomy. Transplantation 81(12):1735-8 (2006)
      • A. Bachmann, R. Ruszat, T. Forster, D. Eberli, M. Zimmermann, A. Muller, T.C. Gasser, T. Sulser, S. Wyler. Retroperitoneoscopic pyeloplasty for ureteropelvic junction obstruction (UPJO): solving the technical difficulties. Eur Urol 49(2):264-72 (2006)
      • A. Bachmann, R. Ruszat, M. Dickenmann, O. Giannini, M. Mayr, J. STieger, T.C. Gasser, T. Sulser. Chyloretroperitoneum with secondary chylothorax after retroperitoneoscopic donor nephrectomy. Urology 66(4):881 (2005)
      • A. Bachmann, L. Schürch, R. Ruszat, S. Wyler, HH Seifert, A. Müller, K. Lehmann, T. Sulser. Photoselective Vaporisation (PVP) versus Transurethral Resection of the Prostate (TURP): A Prospective Bi-Centre Study of Perioperative Morbidity and Early Functional Outcome. Eur Urol 48(6) :965-971 (2005)
      • A. Bachmann, T. Wolff, R. Ruszat, O. Giannini, M. Dickenmann, L. Gurke, J. STieger, T.C. Gasser, C.G. Stief, T. Sulser. Retroperitoneoscopic donor nephrectomy: a retrospective, non-randomised comparison of early complications, donor and recipient outcome with the standard open approach. Eur Urol 48(1):90-6 (2005)
      • A. Bachmann, R. Ruszat, S. Wyler, O. Reich, HH Seifert, A. Muller, T. Sulser. Photoselective vaporisation of the prostate: the basel experience after 108 procedures. Eur Urol 47(6): 798-804 (2005)
      • A. Bachmann, O. Giannini, T. Wolff, M. Dickenmann, R. Ruszat, I. Langer, L. Gurke, T.C. Gasser, O. Reich, C.G. Stief, J. Steiger, T. Sulser. Zetroperitoneoscopic living donor nephrectomy: a comparison with the open approach in respect of early postoperative pain management. Transplant Proc 37(2):609-12 (2005)
      • A. Bachmann, R. Ruszat, S. Wyler, R. Casella, I. Langer, T.C. Gasser, T. Sulser. Pitfall in renal cyst surgery: serous cystadenoma of pancreas mimicking renal cyst. Urology 65(4): 799-800 (2005)
      • A. Bachmann, T. Sulser, C. Jayet, S. Wyler, R. Ruszat, O. Reich, T.C. Gasser, M. Siebels, C.G. Stief, R. Casella. Retroperitoneoscopy-assisted cryoablation of renal tumours using multiple 1.5mm ultrathin cryoprobes: a preliminary report. Eur Urol 47 : 474-479 (2005)
      • T. Sulser, O. Reich, S. Wyler, R. Ruszat, R. Casella, A. Hofstetter, A. Bachmann. Photoselective KTP Laser Vaporisation of the Prostate: First Experiences with 65 Procedures. J Endourology 18(10): 976-981 (2004)
      • A. Bachmann, O. Reich, S. Wyler , R. Ruszat, R. Casella, T. Gasser, A. Hofstetter, T. Sulser. 80W KTP laser vaporisation of the prostate: technique and 6-month results after 70 procedures. Urologist A 43(10): 1161-1170 (2004)
      • F. Peters, R. Ruszat, H.H. Hirsch, A. Bachmann, T. Spicher. "It's moving inside!" Bladder schistosomiasis. Schweiz Rundsch Med Prax 93(4):116-9 (2004)
          • Butt E, Ebbing J, Bubendorf L, Ardelt P. Influence of hematuria and infection
            on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma.
            Biomark Med. 2017 Apr;11(4):347-357.
          • Ardelt PU, Cederqvist M, Barth M, Frankenschmidt A. The SIGHT questionnaire: A
            novel assessment tool for Satisfaction In Genital Hypospadias Treatment. J
            Pediatr Urol. 2017 Feb;13(1)
          • Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V,
            Larré S, di Stasi S, Colombo R, Babjuk M, Malmström PU, Malats N, Irani J, Baniel
            J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero
            P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099
            patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol. 2016
            Nov;34(11):484
          • Ebbing J, Seibert FS, Pagonas N, Bauer F, Miller K, Kempkensteffen C, Günzel
            K, Bachmann A, Seifert HH, Rentsch CA, Ardelt P, Wetterauer C, Amico P, Babel N,
            Westhoff TH. Dynamics of Urinary Calprotectin after Renal Ischaemia. PLoS One.
            2016 Jan 8;11(1)
          • Ardelt PU, Rieken M, Ebbing J, Bonkat G, Vlajnic T, Bubendorf L, Grobholz R,
            Steiger J, Bachmann A, Burkhalter F. Urothelial Cancer in Renal Transplant
            Recipients: Incidence, Risk Factors, and Oncological Outcome. Urology. 2016
            Feb;88:104-10.
          • Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larré S, Di
            Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M,
            Soukup V, Malmström PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK,
            Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes
            RJ, Palou J. The impact of re-transurethral resection on clinical outcomes in a
            large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer
            treated with bacille Calmette-Guérin. BJU Int. 2016 Jul;118(1):44-52.
          • Ardelt PU, Ebbing J, Adams F, Reiss C, Arap W, Pasqualini R, Bachmann A,
            Wetterauer U, Riedmiller H, Kneitz B. An anti-ubiquitin antibody response in
            transitional cell carcinoma of the urinary bladder. PLoS One. 2015 Mar
            5;10(3)
          • Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré
            S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R,
            Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano
            R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R,
            Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J.
            Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer
            patients initially treated with Bacillus Calmette-Guérin: results of a
            retrospective multicentre study of 2451 patients. Eur Urol. 2015 Jan;67(1):74-82.
          • Ardelt PU, Cederquist M, Schoenthaler M, Miernik A, Frankenschmidt A. The
            glandular resection and central embedding modification (GRACE) in Duckett and
            Barcat hypospadias repair. Urol Int. 2013;90(3):358-64.
          • Miernik A, Wilhelm K, Ardelt PU, Adams F, Kuehhas FE, Schoenthaler M.
            Standardised flexible ureteroscopic technique to improve stone-free rates.
            Urology. 2012 Dec;80(6):1198-202.
          • Ardelt PU, Glaser T, Schoenthaler M, Gerharz EW, Frankenschmidt A. Glandular resection and central embedding in hypospadias repair--a novel modification
            resection and central embedding in hypospadias repair--a novel modification of
            the Barcat technique. J Pediatr Surg. 2012 May;47(5):1032-7.
          • Ardelt P, Grünemay N, Strehl A, Jilg C, Miernik A, Kneitz B, Butt E. LASP-1,
            a novel urinary marker for detection of bladder cancer. Urol Oncol. 2013
            Nov;31(8):1591-8.
          • Jilg CA, Neumann HP, Gläsker S, Schäfer O, Leiber C, Ardelt PU, Schwardt M,
            Schultze-Seemann W. Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological
            cell carcinoma; clinicopathological long-term follow-up. Fam Cancer. 2012
            Sep;11(3):387-94.
          • Schoenthaler M, Farin E, Karcz WK, Ardelt P, Wetterauer U, Miernik A. [The
            Freiburg Index of Patient Satisfaction: introduction and validation of a new
            questionnaire]. Dtsch Med Wochenschr. 2012 Mar;137(9):419-24.
          • Miernik A, Wilhelm K, Ardelt P, Bulla S, Schoenthaler M. [Modern urinary stone therapy: is the era of extracorporeal
            stone therapy: is the era of extracorporeal shock wave lithotripsy at an end?]
            Urologist A. 2012 Mar;51(3):372-8.
          • Jilg CA, Neumann HP, Gläsker S, Schäfer O, Ardelt PU, Schwardt M,
            Schultze-Seemann W. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.
            carcinoma. Urol Int. 2012;88(1):71-8.
          • Schoenthaler M, Wilhelm K, Katzenwadel A, Ardelt P, Wetterauer U, Traxer O,
            Miernik A. Retrograde intrarenal surgery in treatment of nephrolithiasis: is a
            100% stone-free rate achievable? J Endourol. 2012 May;26(5):489-93.
          • Ardelt PU, Woodhouse CR, Riedmiller H, Gerharz EW. The efferent segment in
            continent cutaneous urinary diversion: a comprehensive review of the literature.
            BJU Int. 2012 Jan;109(2):288-97.
          • Ardelt PU, Kneitz B, Adam P, Reiss C, Kocot A, Fensterle J, Chen L,
            Pasqualini R, Arap W, Gerharz EW, Riedmiller H. Reactive antibodies against
            bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of
            immunotherapy for high-grade transitional cell carcinoma of the bladder. Cancer.
            2010 Feb 1;116(3):600-9.